First Time Loading...
A

Ambrx Biopharma Inc
NYSE:AMAM

Watchlist Manager
Ambrx Biopharma Inc
NYSE:AMAM
Watchlist
Price: 28 USD 0.07% Market Closed
Updated: May 5, 2024

Ambrx Biopharma Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ambrx Biopharma Inc
Revenue Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
A
Ambrx Biopharma Inc
NYSE:AMAM
Revenue
$7.4m
CAGR 3-Years
-10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$54.3B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$27.5B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Revenue
$28.2B
CAGR 3-Years
4%
CAGR 5-Years
3%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$9.9B
CAGR 3-Years
17%
CAGR 5-Years
26%
CAGR 10-Years
23%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.1B
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
20%

Ambrx Biopharma Inc
Revenue Breakdown

Breakdown by Geography
Ambrx Biopharma Inc

Not Available

Breakdown by Segments
Ambrx Biopharma Inc

Total Revenue: 7.4m USD
100%
License Fees: 3.4m USD
46.5%
Research And Development Services: 2.1m USD
28.9%
Milestones: 1m USD
13.5%
Reimbursements: 820k USD
11.1%
Show More
Show Less

See Also

What is Ambrx Biopharma Inc's Revenue?
Revenue
7.4m USD

Based on the financial report for Dec 31, 2022, Ambrx Biopharma Inc's Revenue amounts to 7.4m USD.

What is Ambrx Biopharma Inc's Revenue growth rate?
Revenue CAGR 3Y
-10%

Over the last year, the Revenue growth was -1%. The average annual Revenue growth rates for Ambrx Biopharma Inc have been -10% over the past three years .